Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology

  • Acquisition adds OLN324, a Phase 3 investigational bispecific antibody for retinal vascular diseases, including wet AMD and diabetic macular edema
  • Accelerates Company's ambition to preserve, restore and enhance vision
  • Builds on Johnson & Johnson's long-standing presence as an innovator in vision

Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., ("Ollin") a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for $2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments. Johnson & Johnson will also enter into a separate development funding agreement with Blackstone Life Sciences ("Blackstone") to support the Phase 3 clinical advancement of OLN324, contingent upon acquisition close.

With this agreement, Johnson & Johnson would add to its pipeline OLN324, an investigational bispecific antibody designed to target two key pathways in retinal diseases, vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2). OLN324 is a next-generation antibody with high Ang2 potency and a small protein format (minibody) that could enable improved control of retinal fluid. It is being developed for conditions including wet age-related macular degeneration (AMD) and diabetic macular edema, which together affect more than 40 million people worldwide and are leading causes of vision loss. 1,2,3

"OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control," said Kip Connor, Vice President, Ophthalmology Disease Area Stronghold Leader, Johnson & Johnson. "The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients."

Johnson & Johnson's combination of scientific, development and commercial capabilities position the Company to advance OLN324 and build on Ollin's promising science. The proposed acquisition would strengthen Johnson & Johnson's leadership in ophthalmology and its commitment to preserve, restore, and enhance vision for millions of people worldwide.

Transaction and financial details

Key terms of the proposed acquisition and related development funding arrangement include:

  • Acquisition of Ollin:
    • Johnson & Johnson will acquire Ollin for $2.2 billion upfront, with the potential for regulatory and commercial milestone payments up to approximately $1.125 billion.
    • The transaction is expected to close before the end of 2026, subject to applicable regulatory approvals and customary closing conditions.
  • Development funding with Blackstone:
    • Blackstone will pay a total of $750 million to Johnson & Johnson over multiple years to fully fund the Phase 3 development of OLN324.
    • In return, Blackstone will be eligible to receive certain regulatory and sales milestone payments as well as single digit royalties.

The accounting treatment will be communicated on or before the close of the transaction.

About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.

Learn more at https://www.jnj.com/ . Follow us @Johnson&Johnson .

Caution Concerning Forward-Looking Statements :
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to the acquisition of Ollin Biosciences. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: the satisfaction of closing conditions for the acquisition; the possibility that the acquisition will not be completed in the expected timeframe or at all; the potential that the expected benefits of the acquisition, if fully completed, may not be realized or may take longer to realize than expected; the potential that the expected benefits and opportunities related to the acquisition may not be realized or may take longer to realize than expected; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com , www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

_____________________________

1 Wong TY, Tan TE. Invest Ophthalmol Vis Sci. 2023;64(15):47. doi:10.1167/iovs.64.15.47

2 Macular Degeneration Association. "What is Macular Degeneration?" Accessed November 13, 2026.

3 Apte RS. N Engl J Med. 2021;385(6):539-547. doi:10.1056/NEJMcp2102061.

Media contact:
J&J Global Media Relations
Media-relations@its.jnj.com

Investor contact:
Jessica Margevich
investor-relations@its.jnj.com

News Provided by Business Wire via QuoteMedia

JNJ
The Conversation (0)
Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 44 th Annual Global Healthcare Conference on Tuesday, June 13 th , at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. Biljana Naumovic, Worldwide Vice President, Oncology, and Peter Lebowitz, Global... Keep Reading...
Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering

Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering

Johnson & Johnson (NYSE: JNJ) and Kenvue Inc. ("Kenvue"), a wholly owned subsidiary of Johnson & Johnson, today announced the pricing of Kenvue's upsized initial public offering ("IPO") of 172,812,560 shares of Kenvue's common stock at a price to the public of $22.00 per share. In addition,... Keep Reading...
Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference

Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 39 th Annual Strategic Decisions Conference on Wednesday, May 31 st , at the New York Hilton Midtown in New York. Joaquin Duato, Chairman of the Board and Chief Executive Officer will represent the Company in a session scheduled at... Keep Reading...

Kaleido Collaborates with Janssen on Metabolic Therapies

Kaleido Biosciences (NADAQ:KLDO) announced a research collaboration with Janssen’s World Without Disease Accelerator, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ). As quoted in the press release: The collaboration will explore the potential for Kaleido’s... Keep Reading...

XBiotech Sells Human Antibody to Janssen for US$750 Million

XBiotech (NASDAQ:XBIT) announced the closing of the sale of its True Human antibody Bermekimab to Johnson & Johnson’s (NYSE:JNJ) Janssen Biotech. As quoted in the press release: Upon closing, Janssen paid XBiotech $750 million, with $75 million held in escrow for 18 months. Should Janssen pursue... Keep Reading...
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

5 Best-performing Canadian Pharma Stocks in 2026

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover, develop and commercialize major innovations amid an increasingly competitive global landscape. Rising technologies such as artificial... Keep Reading...
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2026

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval. However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected... Keep Reading...
Marvel Announces Final Shank3 Data: MB-204 Highly Effective at Reversing Autism Behaviours

Marvel Announces Final Shank3 Data: MB-204 Highly Effective at Reversing Autism Behaviours

Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), a drug discovery company developing novel therapeutics for autism spectrum disorder ("ASD") and related neurodevelopmental disorders, is... Keep Reading...
Medical professional's hand under a digital interface with a glowing cross and circuit design.

Eli Lilly Brings AI to Drug Delivery in METiS TechBio Deal

METiS TechBio (HKEX:7666) could collect up to US$1.1 billion in milestone payments from Eli Lilly and Company (NYSE:LLY) under a new research pact to design lipid nanoparticles that carry medicines to specific tissues in the body.Lipid nanoparticles, or LNPs, carry therapeutic payloads to target... Keep Reading...
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. ("BriaPro"), today announced that four... Keep Reading...

Interactive Chart

Latest Press Releases

Related News